New pill aims to shrink fatty liver in 12 weeks
NCT ID NCT07308548
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental pill called HP515 for people with non-alcoholic fatty liver disease (NAFLD). About 80 adults aged 18 to 65 with at least 10% liver fat will take the drug for 12 weeks. The main goal is to see if it reduces liver fat measured by MRI, while also checking safety and how the body processes the drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAFLD - NON-ALCOHOLIC FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tsinghua Changgung Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 102218, China
-
Chengdu Seventh People's Hospital
RECRUITINGChengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common b vitamin tame fatty liver?
- Could a daily dose of citrus fiber tame fatty liver inflammation?
- New ultrasound test could make liver fat detection quick and painless
- 20,000 seniors join quest to unlock fatty liver secrets
- Eat in 8 hours, heal your liver? new study tests Time-Restricted diet for fatty liver